Floatz logo

Palifermin

Stomatitis

Swedish Orphan Biovitrumprotein_peptidePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Stomatitis cohort.

Asset / SponsorPhaseRating
Datopotamab Deruxtecan
AstraZeneca
Phase 4BB
Methylene Blue
Mayo Clinic
Phase 3BB
DEXAMETHASONE
AstraZeneca
Phase 4BB
MECLOCYCLINE SULFOSALICYLATE
Mucosal Therapeutics
Phase 2B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
US Oncology Research
Phase 2B

View all 17 →

Same molecule, other indications

Palifermin is also rated in:

mucositisDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →